 - Patients may have received up to two prior therapies including vascular endothelial growth factor VEGF, mammalian target of rapamycin mTOR and programmed cell death PD-1PD ligand 1 L1 inhibitors; prior palliative radiation to metastatic lesions is permitted, provided there is at least one measurable andor evaluable lesions that has not been irradiated 